Zydus gets US regulator's PAS for generic version of Mycophenolate Mofetil for injection
The company said the PAS it has received is for site transfer into Jarod.
)
12:00 PM IST
Zydus Lifesciences Ltd on Monday said it has received prior approval supplement nod from the US health regulator to market its generic version of Mycophenolate Mofetil for injection used in combination with other drugs for prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants.
The Prior Approval Supplement (PAS) granted by the US Food & Drug Administration (USFDA) is for Mycophenolate Mofetil for injection of strength 500 mg/vial, the generic equivalent of CellCept injection, the company said in a regulatory filing.
As per the USFDA, PAS refers to a change in either manufacturing or testing of a product applicable to either a specific batch of product or all products that requires the regulator's approval prior to implementation of such changes or sale of the product.
The company said the PAS it has received is for site transfer into Jarod.
"The injection will be manufactured at the group's injectables manufacturing facility at Jarod near Vadodara in Gujarat. This site was recently inspected by the USFDA," it added.
In September 2017, the group was granted approval to market Mycophenolate Mofetil for injection in the strength of 500 mg/vial.
Mycophenolate Mofetil is indicated for use in combination with other drugs such as cyclosporine and corticosteroids for the prophylaxis of organ rejection in patients receiving renal, hepatic or cardiac transplants, the company said.
The group now has 330 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in FY 2003-04, it added.
Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.
RECOMMENDED STORIES
)
)
)
)
)
)
)
)
Zydus gets approval to conduct Phase II clinical study in patients with CAPS in Australia
Zydus Cadila's Covid-19 vaccine ZyCoV-D to be used in these seven states initially
Zydus Cadila gets USFDA nod to market generic cancer drug in US
Zydus Cadila agrees to reduce its Covid vaccine price to Rs 265 a dose, final decision soon: Sources
Cadila Healthcare Q2 profit zooms over 6-fold to Rs 3,002 crore on one-time gain
